Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 22051215)

1.

Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review.

Swift R, Oslin DW, Alexander M, Forman R.

J Stud Alcohol Drugs. 2011 Nov;72(6):1012-8. Review.

PMID:
22051215
2.
3.

A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.

Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, O'Brien CP.

Am J Addict. 2014 Nov-Dec;23(6):591-7. doi: 10.1111/j.1521-0391.2014.12146.x. Epub 2014 Sep 22.

PMID:
25251201
4.

Nalmefene. Alcohol dependence: no advance.

[No authors listed]

Prescrire Int. 2014 Jun;23(150):150-2.

PMID:
25121147
5.

Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.

Hartung DM, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR.

J Subst Abuse Treat. 2014 Aug;47(2):113-21. doi: 10.1016/j.jsat.2014.03.007. Epub 2014 Apr 13.

PMID:
24854219
6.

Can alcohol dependent patients adhere to an 'as-needed' medication regimen?

Sinclair J, Chick J, Sørensen P, Kiefer F, Batel P, Gual A.

Eur Addict Res. 2014;20(5):209-17. doi: 10.1159/000357865. Epub 2014 Feb 15.

PMID:
24557083
7.

Anticonvulsants for alcohol dependence.

Pani PP, Trogu E, Pacini M, Maremmani I.

Cochrane Database Syst Rev. 2014 Feb 13;2:CD008544. doi: 10.1002/14651858.CD008544.pub2. Review.

PMID:
24523233
8.
9.

Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

Syed YY, Keating GM.

CNS Drugs. 2013 Oct;27(10):851-61. doi: 10.1007/s40263-013-0110-x. Review.

PMID:
24018540
10.

Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.

Foa EB, Yusko DA, McLean CP, Suvak MK, Bux DA Jr, Oslin D, O'Brien CP, Imms P, Riggs DS, Volpicelli J.

JAMA. 2013 Aug 7;310(5):488-95. doi: 10.1001/jama.2013.8268.

PMID:
23925619
11.

Opioid antagonists for smoking cessation.

David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ.

Cochrane Database Syst Rev. 2013 Jun 6;6:CD003086. doi: 10.1002/14651858.CD003086.pub3. Review.

12.

Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities.

Rana F, Gormez A, Varghese S.

Cochrane Database Syst Rev. 2013 Apr 30;4:CD009084. doi: 10.1002/14651858.CD009084.pub2. Review.

PMID:
23633366
13.

Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis.

Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, De Geest S, Dobbels F, Lewek P, Urquhart J, Vrijens B; ABC project team.

Drugs. 2013 May;73(6):545-62. doi: 10.1007/s40265-013-0041-3. Review.

14.

The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis.

Del Re AC, Maisel N, Blodgett J, Finney J.

Alcohol Clin Exp Res. 2013 Jun;37(6):1064-8. doi: 10.1111/acer.12067. Epub 2013 Feb 7.

16.

Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

Mann K, Bladström A, Torup L, Gual A, van den Brink W.

Biol Psychiatry. 2013 Apr 15;73(8):706-13. doi: 10.1016/j.biopsych.2012.10.020. Epub 2012 Dec 11.

PMID:
23237314
17.

Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.

Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Smolka MN, Zimmermann US, Wellek S, Kiefer F, Anton RF; PREDICT Study Team.

Addict Biol. 2013 Nov;18(6):937-46. doi: 10.1111/adb.12012. Epub 2012 Dec 12.

PMID:
23231446
18.

A randomized trial evaluating an mHealth system to monitor and enhance adherence to pharmacotherapy for alcohol use disorders.

Stoner SA, Hendershot CS.

Addict Sci Clin Pract. 2012 Jun 8;7:9. doi: 10.1186/1940-0640-7-9.

19.

Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.

Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W.

Contemp Clin Trials. 2013 Mar;34(2):196-204. doi: 10.1016/j.cct.2012.11.002. Epub 2012 Nov 16.

20.

Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW.

Addiction. 2013 Feb;108(2):275-93. doi: 10.1111/j.1360-0443.2012.04054.x. Epub 2012 Oct 17. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk